Regulatory clearance creates an at-home, 28-day cycle option using oral decitabine/cedazuridine on days 1–5 plus venetoclax 400 mg daily after a ramp-up cycle. Efficacy signals in ASCERTAIN-V included ...
An international consortium of pediatric oncology experts has published consensus guidelines on radiation treatment for children with metastatic rhabdomyosarcoma (RMS), offering site-specific ...
Food insecurity identification modeling for Medicare can establish a reliable method of prioritizing members at risk of food ...
Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian dysfunction that drives infertility, menstrual irregularity, and long-term ...
RBM20 truncating variants ( RBM20 tvs) appear to contribute to arrhythmogenic dilated cardiomyopathy (DCM) but with ...
Accelerated approval covers post–BTK inhibitor relapsed/refractory MCL, making sonrotoclax the only BCL2 inhibitor specifically approved for this indication. Independent Lugano-assessed efficacy in ...
In part 2 of her interview with The American Journal of Managed Care®, Deborah Doroshow, MD, PhD, assistant professor of ...
Women with endometriosis have an elevated risk of developing epithelial ovarian cancer, but, when they do develop it, they ...
A formal FDA call for repurposing nominations prioritizes areas where unmet need is high and manufacturer incentives to pursue supplemental approvals are limited. Submissions may be grounded in ...
Young adults with early-onset colorectal cancer (EOCRC), particularly men and non-Hispanic Black and American Indian/Alaskan ...
Scott Shannon, MD, discusses psychedelic therapies, federal policy shifts, and the barriers slowing mental health innovation.
Placebo-controlled evidence across 9013 patients showed a lower composite risk (HR 0.85) driven by reduced worsening HF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results